Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabozantinib, Ipilimumab, and Nivolumab in Advanced Soft Tissue Sarcoma
NCT05836571Phase 2Active, not recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Oct 2023
- Primary completion
- May 2028
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of cabozantinib in soft tissue sarcoma (STS), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Started Oct 2023; status: active, not recruiting.
02
Drugs
cabozantinib
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on NCT05836571.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05836571.